Login
Companies $CRBU
$0.36 +$0.01 (1.7%) After hours
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

cariboubio.com

What Do They Do?

Develops genome-edited, off-the-shelf CAR-T cell therapies for people with blood cancers, using its chRDNA technology to modify donor cells.

How Do They Make Money?

Partners pay for licenses to Caribou's genome-editing technology, related research and development work, and collaboration services. Payments may include upfront and annual fees, milestone payments and royalties on sales; license fees may be paid when the license is transferred, while combined work may be paid over time.

FY2025 revenue

Who Are Their Customers?

Biopharmaceutical partners license Caribou's intellectual property and may work with the company on research and development and collaboration activities.

Do Revenues Turn Into Profits?

No. It lost $148.1M in FY2025.

Operating income, FY2025
−1329% of revenue
▲ +11% (Loss) vs FY2024 (−$166.6M, −1667%)
Net income, FY2025
−1327% of revenue
▲ +1% (Loss) vs FY2024 (−$149.1M, −1492%)
Free cash flow, FY2025
−1007% of revenue
▲ +21% (Loss) vs FY2024 (−$143.1M, −1432%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −27%
vs $2.2M in Q3 FY2025
Net income
▲ +3% (Loss)
vs −$27.5M in Q3 FY2025
  • Jun 11, 2026 Caribou reported follow-up clinical trial data for vispa-cel and CB-011 The update included ANTLER results and the planned design of the pivotal ANTLER-3 trial.
  • Mar 31, 2026 FDA granted CB-011 RMAT designation for multiple myeloma

Growing. Revenue grew 16% in 4 years, from $9.6M in FY2021 to $11.2M in FY2025, about 4% a year.

Narrowed therapy pipeline The older report described CAR-T and CAR-NK programs, including programs for solid tumors and work developing therapies for AbbVie. The latest report focuses on two clinical-stage allogeneic CAR-T candidates for blood cancers.

Who Do They Compete With?

Competes with Novartis, Kite Pharma, Bristol-Myers Squibb, Legend Biotech, Allogene Therapeutics, Atara Biotherapeutics, Cellectis, CRISPR Therapeutics, Fate Therapeutics, AbbVie, Arbor Biotechnologies, Beam Therapeutics, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, Metagenomi Therapeutics, Scribe Therapeutics, Precision BioSciences, Prime Medicine, and Sangamo Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support